I started clicking through demos from “AI‑enabled QMS” vendors because our CAPA backlog was becoming a tragedy and the marketing looked like an aspirin for the whole team. The demos were slick. The slides used the right words: “machine learning”, “natural language”, “automated CAPAs”. But the moment I started asking operational questions, the glow faded. Antworten? Vague. Genau: if a vendor can’t name the model, show the validation, and explain the human‑in‑the‑loop, they’re selling a story, not compliance.
Below is what I now ask, in order, and why each point matters for an EU/US medtech firm operating under ISO 13485 and FDA expectations. In practice this means you can avoid deploying a “clever” tool that fails your next audit or, worse, creates undocumented decisions that affect patient safety.
What “AI‑powered” usually means in demos — and why that’s not enough
Vendors layer AI words over three different realities:
- a simple search index with boosted keywords,
- a rules engine wrapped in NLP to surface likely documents,
- or an actual machine learning model that generates outputs and recommendations.
All three can be useful. The regulatory difference is whether the software is being used for documentation support, decision support, or automated decision‑making. FDA and ISO expectations hinge on the Intended Use — “for Intended Use” validation for FDA, and ISO 13485’s “for use” validation language (see ISO 13485, p.5). If the vendor won’t say which of the above they ship, you don’t know what you’re buying.
Name the model — versioning and provenance matter
Ask the vendor to name the model and version they are using. That includes:
- model family and version (e.g., “transformer-based model X, v2.3”), or the exact search/indexing product if not an ML model,
- whether it’s third‑party (SaaS vendor uses external LLM) or in-house,
- update frequency and change control: how will you be notified of model upgrades?
Why: you must be able to tie a specific behaviour to a specific software version during audits or investigations. If an LLM update changed how the tool classifies nonconformities, you need traceability and evidence of risk re‑assessment.
Show the validation — test cases, pass/fail criteria, and traceable evidence
“Validated” is not a sticker. Validation for QMS software must align with intended use. Practical requests:
- validation plan and protocol (test objectives, acceptance criteria),
- representative test cases and test data sets (including edge cases),
- traceable results showing pass/fail against acceptance criteria,
- evidence of independent reviewer(s) and versioned validation artefacts,
- supplier documentation you can include in your validation basis (per typical purchasing/validation guidance).
To be blunt: if validation is “we tested it internally” with no documented test plan or traceable outputs, it will not survive an audit. Get the artifacts before procurement.
Define the human in the loop — who, when, and how
AI outputs in a QMS are useful only if human decisions are reviewable and traceable. Ask:
- what role is expected to review AI suggestions (engineer, RA, QA),
- clear thresholds for escalation (confidence scores, types of classification that must be human‑confirmed),
- how the human’s decision is captured and linked to the artefact (audit trail, signature, timestamp),
- training material and competence expectations for reviewers,
- how disagreements are logged and used to retrain or tune the model.
In practice this means the system should not be able to auto‑close a CAPA without an auditable human decision recorded. “Automated CAPAs” is a feature you should be sceptical of unless you have the documentation.
What else to check — security, data residency, and change control
AI introduces other vectors you must be able to manage:
- data handling: where is your QMS data used for model training or inference? EU residency, DPAs, and supplier commitments matter,
- logging and reproducibility: can you reproduce the exact output given the same input and model version?
- change control & supplier change notifications: how are model updates handled in the supplier’s lifecycle and how will you reflect that in your QMS?
These are not optional. They feed into risk assessments, PSURs, and Potentially into your clinical evaluation if outputs interact with clinical decision making.
A short checklist I use before accepting an “AI” QMS feature
- Vendor names the model and version, and documents the update policy.
- Vendor provides a validation plan, test cases, and results you can keep in your Technical File.
- There is a documented human‑in‑the‑loop process with traceable review records.
- Supplier provides the documentation you need to build your validation basis (yes — ask for it in the contract).
- Change control and notification procedures for model updates are in the SLA.
- Data residency and DPA terms are explicit for training and inference.
If any of these are missing, the pitch is marketing.
Why this matters to RA/QA teams
To be fair, AI can dramatically reduce time spent finding records, drafting CAPA text, or surfacing repeat complaints. I’ve seen good implementations speed up triage. Granted, if you can’t justify the tool in your validation and risk management records, the benefit evaporates under audit pressure. In the worst case, you create undocumented decisions that complicate corrective actions and vigilance reporting.
In practice this means your procurement and validation plan must require supplier artefacts up front. Don’t ask for “a demo” and sign a contract. Ask for the documents that let you validate the tool against your Intended Use.
What I want to know from you: what’s the most useful single item you ask a vendor about AI in a QMS before you’ll even consider a trial?
Top comments (0)